LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Rating of “Buy” from Analysts

LifeMD, Inc. (NASDAQ:LFMD) has received an average recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $12.00.

LFMD has been the subject of a number of research analyst reports. B. Riley assumed coverage on shares of LifeMD in a report on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price for the company. KeyCorp dropped their price objective on LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research report on Friday, September 20th.

LifeMD Trading Up 4.0 %

Shares of LifeMD stock opened at $4.38 on Tuesday. The firm has a market cap of $188.65 million, a price-to-earnings ratio of -6.26 and a beta of 1.18. LifeMD has a 52-week low of $4.10 and a 52-week high of $12.88. The company’s 50-day simple moving average is $5.13 and its 200-day simple moving average is $7.31. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The firm had revenue of $50.66 million during the quarter, compared to analyst estimates of $48.47 million. During the same period last year, the business posted ($0.23) earnings per share. As a group, equities research analysts anticipate that LifeMD will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On LifeMD

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. G2 Investment Partners Management LLC raised its holdings in shares of LifeMD by 23.9% in the fourth quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock worth $5,704,000 after acquiring an additional 132,850 shares during the last quarter. Vanguard Group Inc. raised its stake in LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares during the last quarter. Bank of New York Mellon Corp raised its stake in LifeMD by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in LifeMD by 261.8% in the 1st quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after purchasing an additional 84,413 shares in the last quarter. Finally, Cantor Fitzgerald L. P. acquired a new stake in shares of LifeMD during the 4th quarter worth about $653,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.